← Back to headlines
Needham Initiates Faeth Therapeutics with Buy Rating
Needham has initiated coverage of Faeth Therapeutics stock with a Buy rating, based on the potential of its cancer drug.
21 Aug, 11:58 — 21 Aug, 11:58
Sources
Showing 1 of 1 sources
